And, the combination of an ERBB1/2/4 inhibitor or a PI3K inhibitor or an AKT inhibitor with (sorafenib/regorafenib + sildenafil) was then shown to profoundly enhanced tumor cell killing in vitro. The gene discussed is EGFR; the disease is neoplasm.